

## **IPSOGEN & Cleveland Clinic Announce Agreement to Identify Biomarkers for Breast Cancer Patients at High Risk for Recurrence**

Marseille, France, Wednesday, 27 October 2004 - Ipsogen announced today that it has signed an agreement with The Cleveland Clinic and Dr. Richard Crownover (Cleveland, USA) to identify molecular markers in early stage breast cancer, which predict patient risk for recurrence. Under this agreement, The Cleveland Clinic and Ipsogen will combine extensive clinical and technical resources to identify prognostic and predictive markers by utilizing large-scale gene expression profiling, respectively.

"Dr. Crownover's team is a global leader in breast cancer management and is pioneering the use of novel, personalized therapeutic modalities to improve clinical management of breast cancer. Applying Ipsogen's large-scale gene expression profiling will enhance current understanding of the pathobiology and heterogeneity of breast cancer, and may identify diagnostic, prognostic and predictive biomarkers to identify patients at high risk for recurrence. Our goal in this synergistic collaboration is to deliver a personalized approach to patient care, providing patients and physicians reliable information to make informed, intelligent treatment decisions," said Dr. Alane Koki, Chief Scientific Officer of IPSOGEN.

"Combining the extensive clinical resources of The Cleveland Clinic with the genomic profiling and bioinformatic techniques developed by Ipsogen will allow us to address some of the most fundamental questions regarding the natural history of breast cancer; we hope that this will benefit our breast cancer patients by rapidly moving the promise of individualized genomic information into clinical reality," said Dr. Richard Crownover, Chief of the Breast Tumor Service in Radiation Oncology at The Cleveland Clinic. David Hicks, M.D., Co-Section Head of the Morphologic Molecular Pathology Laboratories at The Cleveland Clinic, added: "The multidisciplinary collaboration between The Cleveland Clinic and Ipsogen should lead to a great deal of important new information that can directly benefit patient care."

### **About IPSOGEN**

IPSOGEN is an emerging biotechnology company utilising advanced technologies to analyse gene expression and to improve the disease management of cancers. IPSOGEN addresses two main markets : (i) The molecular diagnosis of cancer (i.e; leukaemia, lymphomas, breast cancer) to provide innovative diagnostic tools to clinical centers; (ii) The optimisation of discovery and development of anti cancer drugs, to provide pharmaceutical companies with high value information at the pre-clinical and clinical stages, and accelerate drug development through biomarker discovery and validation. Headquartered in Marseille, France, IPSOGEN has global partnerships and markets its product worldwide.

### **About The Cleveland Clinic Foundation**

The Cleveland Clinic Foundation, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. The Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names The Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey.

**DISCLAIMER**

*This press release contains "forward-looking statements" as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Ipsogen SAS does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Ipsogen SAS, among others, the extent to which Ipsogen's technology platform can be used in large scale gene expression analysis, uncertainty of market acceptance of Ipsogen's technologies or ability to compete against existing technologies.*

**CONTACTS**

IPSOGEN SAS; Luminy Biotech Entreprises, 163 av. de Luminy, 13288 Marseille FR, Cedex 9; Tel. : 33(0)491293090 ; Fax. : 33 (0)491293099 ; Mail : [infos@ipsogen.com](mailto:infos@ipsogen.com); Web : [www.ipsogen.com](http://www.ipsogen.com)